41 reports

You can easily book an appointment with one online.

  • Autoimmune Disease
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

One promising target for cancer treatment is the insulin-like growth factor ## receptor (IGF-##R).

  • Autoimmune Disease
  • China
  • Beijing Biotech Pharmaceutical Co., Ltd.
  • Beijing Tiantan Biological Products Co., Ltd.
  • Shanghai CP Guojian Pharmaceutical Co., Ltd.
  • 4A) CLINICAL SUCCESS OF ANTI-IL17 ANTIBODIES
  • 3) TARGET BACKGROUND

One of the company' s two lead programs targets RORgammaT.

  • Autoimmune Disease
  • United States
  • 4SC Discovery GmbH
  • Advinus
  • AstraZeneca PLC
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products

Encore presentation from the WCOG at ACG2017 ##.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products

The study lasted for ## year.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

PLANS ARE UNDERWAY TO TEST THE HIV-## TAT PROTEIN ALONE IN SOUTH AFRICA AND IN COMBINATION WITH HIV-## ENV IN A PHASE I STUDY IN ITALY.

  • Autoimmune Disease
  • Pharmaceutical
  • Vaccine
  • World
  • Market Size
  • VTP-43742 - DRUG PROFILE

The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ## and ## respectively.

  • Autoimmune Disease
  • Pharmaceutical
  • United States
  • Product Initiative
  • Lycera Corp.
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products

It is a small molecule Janus kinase ##, ## inhibitor.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.
  • 4. Drug/Molecule refers to Primary Intervention only.

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Therapy
  • World
  • Product Initiative
  • Catalyst Pharmaceuticals, Inc.
  • VTP-43742 - DRUG PROFILE

Liraglutide is a glucagon-like peptide-## (GLP-##) receptor agonist.

  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd arGEN-X BV ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Applied BioMath LLC ## ## ## ## ## Amgen Inc ## ## ## ## ## Almirall SA Source: GlobalData' s Pharma Intelligence C

  • Autoimmune Disease
  • Hospital
  • Therapy
  • World
  • Product Initiative

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## Alexion Pharmaceuticals Inc ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## Cytokinetics Inc ## ## ## ## ## ## ## Quintiles IMS Holdings Inc ## ## ## ## ## ## ## CuraVac Inc ## ## ## ## ## ## ## CSL Ltd ##

  • Autoimmune Disease
  • Clinical Trial
  • Drug Discovery And Development
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## Pharmaceutical Product Development LLC ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## MallInckrodt Plc ## ## ## ## ## ## CSL Ltd ## ## ## ## ##

  • Autoimmune Disease
  • Monoclonal Antibody
  • World
  • Product Initiative
  • Novartis AG

As of April 2009, the drug candidate was in Phase II/ III stage of development for rasmussen s encephalitis.

  • Autoimmune Disease
  • Neurological Disorder
  • United States
  • Product Initiative
  • Pfizer Inc.

One confirmed relapse was reported, in Cohort ##.

  • Autoimmune Disease
  • Neurological Disorder
  • United States
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.
  • MYASTHENIA GRAVIS - PIPELINE BY ALPHA CANCER TECHNOLOGIES INC, H1 2018
  • MYASTHENIA GRAVIS - PIPELINE BY APELLIS PHARMACEUTICALS INC, H1 2018

The company provides treatment of myasthenia gravis, multiple sclerosis and autoimmune encephalitis and lupus.

  • Autoimmune Disease
  • Neurological Disorder
  • Pharmaceutical
  • United States
  • Product Initiative
  • ALPHA CANCER TECHNOLOGIES INC
  • MYASTHENIA GRAVIS - PIPELINE BY ALPHA CANCER TECHNOLOGIES INC, H2 2018

The company provides treatment for myasthenia gravis, multiple sclerosis and autoimmune encephalitis and lupus.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Protalex, Inc.

SR ONE LTD.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • United States
  • AbbVie Inc.

Kidney Transplant Rejection - Overview Kidney Transplant Rejection - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2018 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2018 Pre-Registration ## ## Ph

  • Autoimmune Disease
  • Healthcare
  • Therapy
  • United States
  • Product Initiative

Fourteen patients developed ## grade ## toxicities, including lymphopenia in ## patients, hyperglycemia in ##, ALT elevation in ##, thrombocytopenia in ##, lung infection in ##, AST elevation in ##, neutropenia in ##, urinary tract infection in ##, colitis in ##, febrile ne

  • Autoimmune Disease
  • Healthcare
  • Monoclonal Antibody
  • United States
  • Product Initiative

Kidney Transplant Rejection - Overview Kidney Transplant Rejection - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2017 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2017 Pre-Registration ## ## Ph

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.

As of April 2009, the drug candidate was in Phase II/ III stage of development for rasmussen s encephalitis.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Neurological Disorder
  • Therapy
  • AB Science SA

Fourteen patients developed ## grade ## toxicities, including lymphopenia in ## patients, hyperglycemia in ##, ALT elevation in ##, thrombocytopenia in ##, lung infection in ##, AST elevation in ##, neutropenia in ##, urinary tract infection in ##, colitis in ##, febrile ne

  • Autoimmune Disease
  • Cell Therapy
  • Specialty Hospital
  • Transplantation
  • Pluristem Therapeutics Inc.
  • Johnson & Johnson - Dormant Projects

Antiviral activity was also observed against other flaviviruses such as the yellow fever virus and the tick-borne encephalitis virus (TBEV).

  • Autoimmune Disease
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • United States

Organic revenue declined ##%.

  • Autoimmune Disease
  • Immunochemistry Test
  • United States
  • Company Financials
  • GlobalData's company
  • VTP-43742 - DRUG PROFILE

In the experimental autoimmune encephalitis mouse model of MS, short term treatments with CGEN-## resulted in a long term dramatic improvement of disease symptoms.

  • Autoimmune Disease
  • Biotech
  • United States
  • Company
  • Product Initiative
  • TOLERANCE AS A POTENTIAL MECHANISM OF ACTION PROVIDING SUCH LONG-LASTING THERAPEUTIC POTENTIAL.

AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL ESCALIER BIOSCIENCES BV EVELO BIOSCIENCES INC EXICURE INC FUJIFILM KYOWA KIRIN BIOLOGICS CO LTD GALAPAGOS NV GALDERMA SA INNOVIMMUNE BIOTHERAPEUTICS INC JAPAN TOBACCO INC KV##. ## THERAPEUTICS LUPIN LTD PR ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Autoimmune Disease
  • Biotech
  • United States
  • Company
  • Product Initiative

AS OF APRIL 2009, THE DRUG CANDIDATE WAS IN PHASE II/ III STAGE OF DEVELOPMENT FOR RASMUSSEN' S ENCEPHALITIS.

  • Autoimmune Disease
  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • VTP-43742 - DRUG PROFILE

In the experimental autoimmune encephalitis mouse model of MS, short term treatments with CGEN-## resulted in a long term dramatic improvement of disease symptoms.

  • Arthritis
  • Autoimmune Disease
  • Therapy
  • United States
  • Pfizer Inc.

-immunoglobulins in Rasmussen encephalitis with start of treatment in the acute disease stage.

  • Autoimmune Disease
  • Mental Health
  • United States
  • Company Operations
  • Product Initiative